Current Opinion in Supportive and Palliative Care was launched in 2007. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of supportive and palliative care are divided into 12 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Dr Fred Saad obtained his medical degree in 1985 from the University of Montreal, Canada and then completed his residency in urology in 1990. He completed a Fellowship in Urologic Oncology in 1992 and became Chief of Urology at Notre-Dame Hospital of the University of Montreal in 1994. Dr Saad established the urologic oncology clinic and research center at the University of Montreal. He is currently Director of Urologic Oncology and is Director of the Prostate Cancer Research Lab of the Montreal Cancer Institute. In 2004 he was awarded the first Chair in Prostate Cancer at the University of Montreal.
Dr Saad is Professor of Surgery/Urology at the University of Montreal. He was President of the Quebec Urologic Association from 2001 to 2003. He is Chairman of the National Cancer Institute of Canada (NCIC) GU group and the Canadian Uro-Oncology Group and is secretary of the Canadian Prostate Health Council as well as the GU Global. He sits on nine editorial boards and serves as a reviewer for over 30 urology and oncology journals. He has authored/co-authored over 150 peer reviewed articles, 500 scientific abstracts and 15 book chapters. He has been an invited speaker/professor over 200 times in over 20 different countries.
His main research interests include molecular prognostic markers in prostate cancer and new therapeutic approaches to hormone-refractory prostate cancer. Presently he coordinates over 30 clinical and basic research projects in urologic oncology.
Gustavo De Simone
Gustavo De Simone was born in Argentina in 1955 and graduated as a physician in 1979 completing his specialty in medical oncology. He was appointed Medical Director of the Palliative Care Program at Mainetti Comprehensive Cancer Centre in La Plata, Argentina in 1991. Since then he has contributed to the development of specialist palliative care services in Buenos Aires and other cities in Argentina. He has led development of palliative care education mainly at postgraduate level within the University of La Plata (1992 to 1997) and Universidad del Salvador (1998 to present), and has been involved in the development of the research and development programs. He is Medical Director of Pallium Latinoamerica Study Centre (NGO), which has had academic links with Oxford International Centre for Palliative Care since 1993.
In June 2005, Dr De Simone was made Coordinator of Post-graduated Training in Palliative Care (Residence Program) within the Ministry of Health, Buenos Aires Government. He is currently Chief of Education and Research Department at the “Bonorino Udaondo” Public Hospital in Buenos Aires.
In 1998 he became Honorary Professor of Palliative Medicine at the Universidad del Salvador, Buenos Aires, and Director of the Career of Medical Oncology. This is the first Chair in Palliative Medicine in Argentina and provides a focal point for educational developments in South America. Based on his commitments to education, he got the 2003 International Association for Hospice and Palliative Care (IAHPC) Annual “Vittorio Ventafridda Award”.
In 2009 he was made Director of the working group on End of Life Decisions at the Medical Ethics Committee of the National Academy of Medicine.
Dr Allan Lipton is Professor of Medicine and Oncology at the M.S. Hershey Medical Center in Hershey, Pennsylvania, USA. Dr Lipton has a longstanding interest in the natural history and treatment of bone metastases. His group was the first in the US to treat a patient with pamidronate for bone metastases and also the first in the world to treat patients with zoledronic acid.
James R. Berenson
Dr Berenson has specialized in research related to myeloma and metastatic bone disease both in the basic and clinical areas for more than 20 years. He has been involved in many of the major breakthroughs that have brought new treatments for patients with these diseases resulting in both an improvement in the length and quality of their lives.
He serves as a member of the National Institutes of Health–Center for Scientific Review, Clinical Oncology Study Section. He is a member of the Scientific Boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation. He serves on both the Foundation and the Scientific Boards of the Leukemia, Lymphoma and Myeloma Society. He also works with many other groups known for their work in multiple myeloma and bone metastases.
After receiving a Bachelor of Science with Distinction from Stanford University, he earned his Doctorate in Medicine from the University of California at San Diego. Dr Berenson completed his internship and residency in internal medicine at the University of Utah Medical Center and fellowships in hematology/oncology at the University of California at Los Angeles (UCLA). He is certified by the American Board of Internal Medicine in both internal medicine and medical oncology. He has been affiliated most recently with Cedars–Sinai Medical Center in Los Angeles and served as the Director of the Multiple Myeloma and Bone Metastasis Programs in the Department of Medicine, Division of Hematology/Oncology. Dr Berenson has performed research as a member of the Departments of Medicine and Biological Chemistry at the UCLA School of Medicine and has served as Chief of Medical Oncology and Cancer Research as well as Director of Research at the Greater Los Angeles Veterans Administration Healthcare Systems. Dr Berenson has authored and co-authored numerous books, articles, and abstracts in journals including Blood, Cancer, Cancer Research, Journal of Clinical Investigation, Journal of Clinical Oncology, New England Journal of Medicine, and Science.
In addition to his research interests in myeloma and metastatic bone disease, he also studies antibodies, T-cell receptors, cytokines, cancer genes, viruses and blood vessel development. Dr Berenson has also conducted numerous clinical trials related to the treatment of multiple myeloma and metastatic bone disease. Because he is internationally known for his expertise and accomplishments in these areas, he has also been asked to give numerous lectures and organize many meetings both nationally and internationally.
Dr Berenson has a private practice which specializes in the treatment of patients with myeloma and metastatic bone disease. He is also President and Chief Executive Officer of Oncotherapeutics, Inc., a corporation that conducts clinical trials related to myeloma and metastatic bone disease as well as other cancers throughout the United States.